"Our state health plan is under siege because of the cost of this one type of drug," Folwell told Axios. "If we had stayed the course, there was a potential doubling of the premium on state employees."
The jury is still out on the program, he said. While costs are still increasing, "we're not projecting another 50% increase."
[
add
]
[
|
|
...
]